

EFFICACY OF MOBIDERM BANDAGE FOR INTENSIVE PHASE OF LYMPHEDEMA TREATMENT

MOBILITY Study: Safety and efficacy of a Mobiderm® compression bandage during intensive phase of decongestive therapy in patients with breast cancer-related lymphedema: A randomized controlled trial

Anita Dhar, Anurag Srivastava, Ravindra M Pandey Prasanna Shrestha, Stéphanie Villet, Arun Rekha Gogia.
Lymphatic Research and Biology. 2022 June 8


METHODOLOGY

- Randomized Controlled Study realized in India between 2015 and 2017 in two parallel treatment groups:
 - MOBIDERM Group: Cotton band (Thuasne) + MOBIDERM band + Biflexideal
 - Control group: Cotton band (Thuasne) + ortho cotton wool soft pad (as used in current treatment in India) + Biflexideal
- 50 patients with Breast Cancer Related Lymphedema (BCRL) followed for 15 days during their intensive phase
- Primary outcome: Change in affected limb volume between Day 0 and Day 15.
- Secondary outcomes: Changes in symptom scores (pain/heaviness) by visual analog scale, safety

RESULTS

1

Lymphedema volume reduction is higher with MOBIDERM bandage




When adjusting for baseline volume, a reduction at Day 15 in affected limb volume was observed in both the Mobiderm and control groups (by 19.0% and 8.6% respectively). The between-group mean difference in volume was 256mL in favor of the Mobiderm group ($p = 0.003$).

After adjustment for baseline excess volume, a reduction at Day 15 in excess limb volume* was observed in both the Mobiderm and control groups (by 57.3% and 25.1% respectively). The between-group mean difference in volume was 220.2mL in favor of the Mobiderm group ($p = 0.006$).

*The excess limb volume is calculated by measuring the difference of volume between the healthy and affected arms. This difference corresponds to the volume of lymphedema.

2

A greater reduction of pain and heaviness in Mobiderm group



After 15 days of intensive phase, pain and heaviness were significantly lower in both groups (0.48 and 1.62 in Mobiderm and control groups respectively), with a significantly greater reduction in the Mobiderm group ($p = 0.001$).

3

A good tolerability of Mobiderm bandage

No adverse event related to MOBIDERM bandage has been observed during the treatment period.

KEY MESSAGES

- The use of MOBIDERM in a multilayer compression bandaging during intensive phase is associated to:
 - a higher reduction of lymphedema volume
 - a greater reduction of symptoms associated to lymphedema like pain and heaviness
- MOBIDERM is well tolerated